Get the Stockscreener App
1.64
8.38%
-0.15
After Hours:
1.62
-0.02
-1.22%
Cognition Therapeutics Inc stock is traded at $1.64, with a volume of 1.22M.
It is down -8.38% in the last 24 hours and up +5.81% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$1.79
Open:
$1.79
24h Volume:
1.22M
Relative Volume:
0.23
Market Cap:
$120.58M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-2.0759
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
-2.38%
1M Performance:
+5.81%
6M Performance:
+267.88%
1Y Performance:
+248.27%
1-Day Range:
$1.60
$1.79
1-Week Range:
$1.53
$1.83
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2403 SIDNEY STREET, PITTSBURGH
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.64 | 157.92M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Will Cognition Therapeutics Inc. stock maintain momentum in 2025Quarterly Growth Report & AI Forecast for Swing Trade Picks - newser.com
How to use a screener to detect Cognition Therapeutics Inc. breakoutsPortfolio Performance Summary & Weekly Watchlist of Top Performers - newser.com
Why Cognition Therapeutics Inc. stock is a value investor pickMarket Risk Analysis & High Accuracy Swing Entry Alerts - newser.com
Strategies to average down on Cognition Therapeutics Inc.Earnings Overview Summary & Weekly Sector Rotation Insights - newser.com
What analyst consensus says on Cognition Therapeutics Inc. stock2025 Volatility Report & Smart Allocation Stock Tips - newser.com
Why Cognition Therapeutics Inc. stock appeals to dividend seekersMarket Performance Summary & Accurate Intraday Trading Signals - newser.com
Will Cognition Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Catalysts & Reliable Price Action Trade Plans - newser.com
Using AI based signals to follow Cognition Therapeutics Inc.July 2025 Patterns & Community Consensus Trade Alerts - newser.com
Why Cognition Therapeutics Inc. stock is a must watch in 2025July 2025 EndofMonth & Comprehensive Market Scan Insights - newser.com
Will earnings trigger a reversal in Cognition Therapeutics Inc.Weekly Profit Analysis & Weekly High Momentum Picks - newser.com
Will Cognition Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Analyst Calls & Weekly Stock Breakout Alerts - newser.com
Analyzing Cognition Therapeutics Inc. with multi timeframe chartsGold Moves & AI Driven Stock Movement Reports - newser.com
Using Python tools to backtest Cognition Therapeutics Inc. strategiesJuly 2025 Institutional & Safe Capital Investment Plans - newser.com
Cognition Therapeutics Inc. stock volume spike explained2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
Relative strength of Cognition Therapeutics Inc. in sector analysis2025 EndofYear Setup & Free Expert Verified Stock Movement Alerts - newser.com
3,670,187 Stock Options of Cognition Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-NOV-2025. - MarketScreener
2,541,781 Restricted Stock Units of Cognition Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-NOV-2025. - MarketScreener
Published on: 2025-10-31 05:52:59 - newser.com
Published on: 2025-10-31 04:16:22 - newser.com
What drives Cognition Therapeutics Inc stock priceResistance Breakout Alerts & Fast Growing Investment Ideas - earlytimes.in
Cognition Therapeutics (NASDAQ:CGTX) Stock Price Down 0.6%What's Next? - MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):